ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Carbamazepine

Also written as “carbamazepine”, “Mirdametinib and Carbamazepine” and “Radiprodil with Carbamazepine”.

Its studies are mostly in Epilepsy · Bipolar Disorder · Tuberous Sclerosis · Neuralgia · Hepatitis C, led by 4 companies.

Drug pageCarbamazepine: every studyAll 49 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 11, 20256 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GRIN Therapeutics21 open or runningphase 1since Apr 11, 2025Apr 11, 2025none ahead
H. Lundbeckits history only20 open or runningphase 3since May 21, 2010Mar 1, 2010none ahead
Novartisits history only10 open or runningphase 4since Mar 17, 2010Mar 17, 2010none ahead
Validus Pharmaceuticalsits history only10 open or runningphase 4since Nov 24, 2015Nov 24, 2015none ahead

Also a collaborator on its studies: Parexel, Avance Clinical Pty, Arvinas Estrogen Receptor, Ligand Pharmaceuticals, ICON Clinical Research and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GRIN Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 11, 2025First study: phase 1 study in Tuberous SclerosisFirst studyNCT06965881 · 30 enrolled · Australia
  2. Oct 8, 2026Phase 1 study in Healthy Adult ParticipantsNCT07884734 · 36 enrolled · United States

TargetBeta

“Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
QuinidineruleOtsukaphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 2 GRIN Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07884734Healthy Adult Participants · United States1Active, not recruitingOct 31, 202636
NCT06965881Tuberous Sclerosis · Australia1TerminatedJul 8, 202530

How it is read

Names in the registry

  • “Carbamazepine”, 13 entries
  • “carbamazepine”, 2 entries
  • “Mirdametinib and Carbamazepine”, 1 entry
  • “Radiprodil with Carbamazepine”, 1 entry
  • “Intravenous Carbamazepine (IV CBZ)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.